Edition:
United Kingdom

Fate Therapeutics Inc (FATE.OQ)

FATE.OQ on NASDAQ Stock Exchange Global Market

4.43USD
12 Dec 2017
Change (% chg)

$0.29 (+7.13%)
Prev Close
$4.14
Open
$4.20
Day's High
$4.55
Day's Low
$4.11
Volume
90,407
Avg. Vol
63,404
52-wk High
$5.67
52-wk Low
$2.40

Latest Key Developments (Source: Significant Developments)

Fate Therapeutics reports Q2 2016 financial results
Monday, 8 Aug 2016 

Fate Therapeutics Inc : Fate Therapeutics reports second quarter 2016 financial results . Q2 revenue $1.0 million versus I/B/E/S view $866,000 . Says Ind Filing For Allogeneic Memory Like NK cell cancer immunotherapy planned for 2016 .Qtrly loss per share $0.29.  Full Article

Fate Therapeutics says $10.3 million common stock private placement
Monday, 8 Aug 2016 

Fate Therapeutics Inc: Fate Therapeutics announces $10.3 million common stock private placement . Investors have agreed to purchase 5.3 million shares of company's common stock at a price of $1.96 per share .Expects to use proceeds from transaction primarily to advance its pipeline of programmed cellular immunotherapies among others.  Full Article

Fate Therapeutics announces FDA fast track designation for Protmune
Monday, 20 Jun 2016 

Fate Therapeutics Inc : Says FDA has granted fast track designation for Protmune .Fate Therapeutics announces FDA fast track designation for Protmune.  Full Article

Fate Therapeutics qtrly net loss $0.29 per share
Monday, 9 May 2016 

Fate Therapeutics Inc : Qtrly net loss per common share, basic and diluted $0.29 . Fate therapeutics reports first quarter 2016 financial results . Q1 revenue $1.3 million .Q1 revenue view $795,000 -- Thomson Reuters I/B/E/S.  Full Article

Fate Therapeutics Inc announces FDA clearance of investigational new drug application for ProTmune for prevention of acute GvHD and CMV infection
Tuesday, 26 Jan 2016 

Fate Therapeutics Inc:Announces FDA clearance of investigational new drug application for ProTmune for prevention of acute GvHD and CMV infection.Plans to initiate a multi-center, randomized, controlled Phase 1/2 clinical trial in adult patients with hematologic malignancies undergoing mobilized peripheral blood hematopoietic cell transplantation in mid-2016.  Full Article

BRIEF-Fate Therapeutics announces initial clinical data from ongoing first-in-human voyage study of FATE-NK100

* Fate Therapeutics announces initial clinical data from ongoing first-in-human voyage study of Fate-NK100 for relapsed / refractory acute myelogenous leukemia at SITC 2017 annual meeting